Current and future use of umifenovir in patients with COVID-19
At the time of print, the evidence for using umifenovir in COVID-19 is mainly theoretical. The published clinical trials have contradicting results. The decision to use umifenovir in COVID-19 should be individualized, considering the "experimental" nature of this treatment.
Saved in:
Main Authors: | Yu. Yu. Kiselev (Author), K. A. Zagorodnikova (Author), D. V. Ivashchenko (Author), A. V. Krykov (Author), I. N. Sychev (Author), A. S. Matveev (Author), K. B. Mirzaev (Author), V. A. Otdelenov (Author), V. M. Tsvetov (Author), A. V. Dmitriev (Author), V. V. Poroikov (Author), D. A. Sychev (Author) |
---|---|
Format: | Book |
Published: |
Izdatelstvo OKI,
2020-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Current and future use of aminodihydrophthalazindione sodium in patients with COVID-19, including for «cytokine storm» therapy
by: V. M. Tsvetov, et al.
Published: (2020) -
Current and future use of remdesivir in patients with COVID-19
by: V. M. Tsvetov, et al.
Published: (2020) -
Rationale for use mefloquine for COVID-19 treatment
by: V. A. Otdelenov, et al.
Published: (2020) -
Current and future use of angiotensin II receptor blockers in patients with COVID-19
by: A. V. Matveev, et al.
Published: (2020) -
Current and future use of colchicine in patients with COVID-19
by: Yu. Yu. Kiselev, et al.
Published: (2020)